Tricida (TCDA) Misses Q1 EPS by 1c

Tricida (NASDAQ: TCDA) reported Q1 EPS of ($0.78), $0.01 worse than the analyst estimate of ($0.77).

“With the completion of our successful long-term extension trial, we are now focused on the NDA submission in the second half of this year under the Accelerated Approval Program,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. “We are also keenly focused on our prelaunch activities, in particular in advancing disease education and awareness of the central role metabolic acidosis plays in exacerbating bone, muscle and kidney disease.”

For earnings history and earnings-related data on Tricida (TCDA) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance